2024年4月9日 · WHO estimated that in 2022, approximately 242 000 people died from hepatitis C, mostly from cirrhosis and hepatocellular carcinoma (primary liver cancer). Direct-acting antiviral medicines (DAAs) can cure more than 95% of persons with hepatitis C infection, but access to diagnosis and treatment is low.

2024年4月9日 · 丙肝病毒是一种血液传播病毒，大多数感染通过血液接触造成，这包括不安全注射做法、不安全的卫生保健、输入未经筛查的血液、注射吸毒以及可导致血液接触的性行为。 全球估计有5000万慢性丙肝病毒感染者，每年约有100万新发感染病例。 世卫组织估计，2022年，约有242000人死于丙型肝炎，主要缘于肝硬化和肝细胞癌（原发性肝癌）。 直接抗病毒药物（DAAs）可使95%以上的丙肝感染者得到治愈，但诊断和治疗可及性很低。 目前尚无针对丙 …

2022年6月24日 · Updated WHO Guidance on hepatitis C (HCV) infection was released today during a joint WHO-EASL-CDC symposium at the EASL International Liver Congress 2022 in London. These guidelines recommend a radical simplification of the care pathway to overcome barriers in access to HCV testing and treatment.

Implementation considerations for HBsAg and HCV antibody serological testing 68 9. DETECTION OF VIRAEMIC HBV INFECTION – to guide who to treat or not treat 70

Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA. 3.0 IGO. Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris. Sales, rights and licensing.

We recommend delivery of HCV testing and treatment at peripheral health or community-based facilities, and ideally at the same site, to increase access to diagnosis, care and treatment. These facilities may include primary care, harm reduction sites, …

HCV: To test for serological evidence of past or present infection in adults and children (>18 months of age), an HCV serological assay (antibody or antibody/antigen) using either RDT or laboratory-based immunoassay formats that meets minimum performance standards is …

5.1 Screening to identify persons with HCV infection 43 5.2 When to confirm a diagnosis of chronic HCV infection 47 6. RECOMMENDATIONS ON CARE OF PEOPLE INFECTED WITH HCV 50 6.1 Screening for alcohol use and counselling to reduce moderate and high levels of alcohol intake 50 6.2 Assessing the degree of liver fibrosis and cirrhosis 54 CONTENTS

10 July 2024 – The World Health Organization (WHO) has prequalified the first hepatitis C virus (HCV) self-test which can provide a critical support in expanding access to testing and diagnosis, accelerating global efforts to eliminate hepatitis C.

WHO recommends offering testing for HCV to all adults in settings where prevalence of HCV antibodies in the general population is over 2%, and focused testing in all settings for most affected populations,

2024年4月11日 · This is the first consolidated WHO report on viral hepatitis epidemiology, service coverage and product access, with improved data for action. This report presents the latest estimates on the disease burden and the coverage of essential viral hepatitis services from 187 countries across the world.

2024年7月22日 · Safe and effective vaccines are available to prevent hepatitis B virus (HBV). This vaccine also prevents the development of hepatitis D virus (HDV) and given at birth strongly reduces transmission risk from mother to child. Chronic hepatitis B …

These are the first WHO guidelines on testing for chronic HBV and HCV infection and complement published guidance by WHO on the prevention, care and treatment of chronic hepatitis C and hepatitis B infection.

WHO estimated that in 2015, 71 million persons were living with chronic hepatitis C virus (HCV) infection worldwide and that 399 000 died from cirrhosis or hepatocellular carcinoma caused by HCV infection (1). Among the WHO regions, the Eastern Mediterranean Region had the highest prevalence (2.3%) followed by the European Region (1.5%).

Hepatitis C virus (HCV) infection is a major public health problem and cause of chronic liver disease that leads to approximately 400 000 deaths annually. In 2019 WHO estimated that 58 million persons were chronically infected and living with hepatitis C, with a disproportionately high burden in low- and middle-income countries (LMICs).

2025年3月8日 · Hepatitis C virus (HCV) is a worldwide health hazard, and in chronic form (nowadays affecting 50 million people – World Health Organization data) can be lethal. To forestall it, preventive ...

4 天之前 · In 2016, the World Health Organisation (WHO) set a target to eliminate HCV as a major health treat by 2030 1. Italy had been making progress towards HCV elimination but faced challenges during the ...

Hepatitis C virus (HCV) infection is a major public health problem and cause of chronic liver disease that leads to approximately 399 000 deaths annually. In 2019, only 21% of the 58 million persons with chronic HCV infection had been diagnosed, and 13%, treated.

Hepatitis C virus (HCV) infection is a major public health problem. HCV infection causes chronic liver disease that leads to nearly 400 000 deaths annually. In 2019 WHO estimated that 58 million persons were chronically infected and living with hepatitis C, with a disproportionately high burden in low- and middle-income countries (LMICs) (1).

HCV Testing and Linkage to Care; When and in Whom to Initiate HCV Therapy; Overview of Cost, Reimbursement, and Cost-Effectiveness Considerations for Hepatitis C Treatment Regimens; Monitoring Patients Who Are Starting HCV Treatment, Are on Treatment, or Have Completed Therapy; Incomplete Adherence; HCV Resistance Primer